RNS Number : 2533C
Nektar Therapeutics
10 October 2022
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
FOR IMMEDIATE RELEASE
10 October 2022
Nektar Therapeutics
Rule 2.9 Announcement
In accordance with Rule 2.9 of the UK City Code on Takeovers and Mergers (the "Code"), Nektar Therapeutics ("Nektar") confirms that, as at the close of business on October 6, 2022, it has issued and outstanding 187,954,482 shares of common stock, par value $0.0001 each ("Common Stock"). Nektar does not hold any shares of Common Stock in treasury.
The Common Stock is admitted to trading on the NASDAQ exchange under the trading symbol NKTR, CUSIP number 640268108, and ISIN number US6402681083.
Enquiries:
| Nektar Therapeutics |
|
| Jennifer Ruddock |
|
| |
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.